8-K: Zomedica Reports Record First Quarter Revenue, Up 14% to $6.3 Million

Zomedica's first quarter 2024 revenue reached a record $6.3 million, a 14% increase year-over-year, driven by growth in both therapeutic devices and diagnostics segments.

Summary

• Zomedica's revenue for the first quarter of 2024 was $6.3 million, a 14% increase compared to $5.5 million in the same period last year.
• The growth was fueled by a 9% increase in the Therapeutic Devices segment and an 86% increase in the Diagnostics segment.
• Consumable revenues reached $4.0 million, up 7% year-over-year, representing 64% of total sales.
• Capital revenues grew to $2.2 million, a 30% increase compared to the first quarter of 2023.
• The company's gross margin was 66% for the quarter, and when adjusted for one-time items, it exceeds 69%.
• Total cash used during the quarter was $9.6 million, but when adjusted for non-recurring items, the non-GAAP operating burn was approximately $4.4 million.
• Operating expenses increased by 28% to $14.5 million, but when adjusted for one-time items and QBT operations, the increase was just over 20%.
• Research and development expenses doubled to $1.8 million, primarily due to the QBT acquisition and investments in product certifications and AI integration.
• The net loss for the quarter was $9.2 million, or $0.01 per share, compared to a net loss of $6.4 million, or $0.007 per share, in the first quarter of 2023.
• Zomedica had $90.9 million in cash, cash equivalents, and available-for-sale securities as of March 31, 2024.
• The company maintains its full-year 2024 revenue guidance of $31 to $35 million, representing a potential 39% increase over 2023 revenue.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with strong revenue growth and positive future guidance, but also increasing losses and operating expenses. The sentiment is cautiously optimistic, reflecting the company's potential but also the challenges it faces.

Positives

• The company achieved record first-quarter revenue, demonstrating strong growth.
• The Diagnostics segment showed substantial growth, indicating strong market acceptance of their products.
• The company's gross margin remained strong at 66%, and over 69% when adjusted for one-time items.
• Zomedica's non-GAAP operating burn was in line with expectations and annual guidance.
• The company has a strong cash position of $90.9 million.
• Zomedica is projecting significant revenue growth for the full year 2024.

Negatives

• The company experienced a net loss of $9.2 million for the quarter, an increase from the $6.4 million loss in the same period last year.
• Operating expenses increased by 28%, impacting profitability.
• Cash reserves decreased from $100.5 million at the end of 2023 to $90.9 million.
• Non-GAAP EBITDA loss was $7.5 million, or $6.2 million when adjusted for non-recurring items, and $5.3 million when further adjusted for QBT integration costs.

Risks

• The company's net loss increased compared to the same quarter last year.
• Operating expenses are increasing, which could impact future profitability.
• The company's cash reserves are decreasing due to ongoing operations and acquisition-related expenses.
• The company is reliant on the successful launch of new products to achieve its revenue targets.
• The company is subject to risks related to regulatory approvals, competition, and the integration of acquisitions.

Future Outlook

Zomedica expects full-year 2024 revenue to be in the range of $31 to $35 million, with revenue increasing sequentially throughout the year and the majority of revenue expected in the back half of the year. This guidance does not include any potential benefits from future acquisitions.

Management Comments

• Zomedica Chief Executive Officer, Larry Heaton, stated that the company delivered the strongest first quarter in company history.
• Mr. Heaton noted the positive impact of the expanded portfolio and the growth of the commercial organization.
• Mr. Heaton expressed enthusiasm about the opportunity for Zomedica and its strategy to achieve profitability and grow revenue to $100 million and beyond.

Industry Context

Zomedica operates in the veterinary health industry, which is experiencing growth due to increased pet ownership and advancements in veterinary medicine. The company's focus on point-of-care diagnostics and therapeutics aligns with the industry trend towards more efficient and accessible veterinary care. The company is competing with other veterinary diagnostic and therapeutic companies, and the success of their strategy will depend on their ability to innovate and capture market share.

Comparison to Industry Standards

• Zomedica's 14% revenue growth is a positive sign, but it is important to compare this to other veterinary health companies such as IDEXX Laboratories and Zoetis, which are larger and more established players in the industry.
• IDEXX Laboratories, for example, reported a 9% organic revenue growth in their most recent quarter, while Zoetis reported a 7% operational revenue growth. Zomedica's growth rate is higher, but it is from a smaller base.
• Zomedica's gross margin of 66% is competitive, but it is important to note that IDEXX Laboratories has a gross margin of around 58% and Zoetis has a gross margin of around 70%.
• Zomedica's operating expenses are increasing, which is a concern, and it will be important to see if they can achieve economies of scale as they grow. IDEXX and Zoetis have much lower operating expenses as a percentage of revenue due to their scale.
• Zomedica's cash burn is also a concern, and they will need to manage their cash carefully to achieve profitability. IDEXX and Zoetis are both profitable and generate significant cash flow.

Stakeholder Impact

• Shareholders may be encouraged by the revenue growth but concerned about the increasing losses.
• Employees may be motivated by the company's growth and expansion.
• Customers may benefit from the company's innovative products and services.
• Suppliers may see increased demand for their products and services.
• Creditors may be monitoring the company's cash flow and financial performance.

Next Steps

• The company will continue to execute its strategy to drive growth in 2024 and beyond.
• Zomedica will focus on maintaining industry-leading margins and capturing efficiencies.
• The company expects to launch new products during 2024.
• Zomedica will host a conference call to discuss the financial results.

Key Dates

Keywords

Zomedica, veterinary health, diagnostics, therapeutic devices, revenue, gross margin, financial results, Q1 2024, operating expenses, net loss, EBITDA, cash, guidance